Replies to post #827 on Cardiff Oncology, Inc. (CRDF)

[briphelps]

He bought that stock up above $7 per share before he left. Do more homework on Welch.
He specializes in comm market products.
Posard was asked to stay but has a bug up his A! So he left! Big mistake on Posards part.
Welch just now received 750k options form3
TroveGene is the best in breed. Only co ahead of the game. Revenues next.
Publications too. $15- $20 year end, buy out by next year $40.00 plus per share
ILMN I think.